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Abstract
Background: Angiotensin I-converting enzyme (ACE) has two functional N- and C-domain active centers that display
differences in the metabolism of biologically-active peptides including the hemoregulatory tetrapeptide, Ac-SDKP,
hydrolysed preferentially by the N domain active center. Elevated Ac-SDKP concentrations are associated with reduced
tissue fibrosis.
Results: We identified a patient of African descent exhibiting unusual blood ACE kinetics with reduced relative hydrolysis of
two synthetic ACE substrates (ZPHL/HHL ratio) suggestive of the ACE N domain center inactivation. Inhibition of blood ACE
activity by anti-catalytic mAbs and ACE inhibitors and conformational fingerprint of blood ACE suggested overall
conformational changes in the ACE molecule and sequencing identified Ser333Trp substitution in the N domain of ACE. In
silico analysis demonstrated S333W localized in the S1 pocket of the active site of the N domain with the bulky Trp adversely
affecting binding of ACE substrates due to steric hindrance. Expression of mutant ACE (S333W) in CHO cells confirmed
altered kinetic properties of mutant ACE and conformational changes in the N domain. Further, the S333W mutant
displayed decreased ability (5-fold) to cleave the physiological substrate AcSDKP compared to wild-type ACE.
Conclusions and Significance: A novel Ser333Trp ACE mutation results in dramatic changes in ACE kinetic properties and
lowered clearance of Ac-SDKP. Individuals with this mutation (likely with significantly increased levels of the hemoregulatory
tetrapeptide in blood and tissues), may confer protection against fibrosis.
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Introduction
Angiotensin I-converting enzyme (ACE, CD143) is a Zn2+
carboxydipeptidase which plays a key role in the regulation of
blood pressure and also in the development of vascular pathologies
and tissue remodeling. ACE is constitutively expressed on the
surface of endothelial cells, epithelial, neuroepithelial and cells of
immune system (macrophages and dendritic cells) as a membrane-
bound protein and has been designated as CD143. Two
homologous domains (N and C domains) comprise the majority
of the structure of somatic ACE (sACE) and each contain a
functional Zn2+ binding active center reviewed in [1–2].
The three-dimensional crystal structure of sACE is still
unknown. However, the model of the two-domain ACE has been
recently suggested [3–4] based on the solved crystal structures of
the C and N domains [5–6], epitope mapping of mAbs to ACE
[7], and, on the electron microscopy picture of sACE [3].
Several mutations in ACE have been described: with several
producing familial elevation of blood ACE due to effects on the
rate of ACE shedding such as P1199L [8–11], Y465D [4], and
R532W [12]. In contrast, other ACE mutations abolish trans-
membrane anchoring to cell membrane resulting in direct ACE
secretion into the blood, i.e. W1197X [13], IVS25+1G.A [14].
Finally, yet other ACE mutations such as transport – defective
ACE mutation - Q1069R [15] and likely many others [16]
impaired trafficking to the cell surface and caused renal tubular
dysgenesis due to almost complete absence of catalytically ACE on
the cell surface.
We now report a novel ACE mutation, where residue
substitution (S333W) near the active site, altered kinetic charac-
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teristics of the N domain active center of somatic ACE. Mutated
ACE exhibited decreased hydrolysis of physiological, N domain
specific substrate Ac-SDKP, a negative regulator of the hemato-
poiesis [17] with strong anti-fibrotic properties [18]. Potential




The study was approved by the Institutional Review Boards of
the University of Chicago and the University of Illinois at Chicago.
Participants provided their written informed consent to participate
in this study. The IRBs approved this consent procedure. Serum
ACE levels were assessed in serum present in the University of
Chicago Biobank obtained from patients with different sarcoidosis
phenotypes (along with controls). One patient (#27) was found to
have serum ACE with an unusual kinetic characteristics –low (0.7)
ZPHL/HHL ratio - normal value -1.0560.05 [20].
ACE activity assay
ACE activity in serum/plasma or culture fluids or lysates from
ACE-expressing cells was measured using a fluorimetric assay with
two ACE substrates (2 mM Z-Phe-His-Leu or 5 mM Hip-His-Leu
[21–22], respectively. Briefly, 40 ml aliquots of samples diluted in
PBS-BSA (0.1 mg/ml), were added to 200 ml of ACE substrate
and incubated for the appropriate time at 37uC. The His-Leu
product was quantified fluorometrically, via complexing with
ortho-phtaldialdehyde. Determination of the ratio of hydrolysis of
the two substrates (ZPHL/HHL) was performed as described [20].
In some experiments samples containing any sources of WT or
mutant ACEs were pre-incubated during 1 hour with different
ACE inhibitors (1 mM) or anti-ACE mAbs (10 mg/ml).
Figure 1. ACE activity in human serum. A–B. ACE activity in 85 samples of human serum from patients with different pulmonary diseases and
unrelated patients (served as a controls) - TRIDOM study, was quantified using a spectrofluorometric assay with Hip-His-Leu (A-5 mM) and Z-Phe-His-
Leu (B-2 mM) as substrates. Data expressed as % of individual ACE’s activity from mean value for whole population (33.0 mU/ml with Hip-His-Leu).
Bars highlighted with blue - samples with values of ACE activity higher than mean + 2SD. Bar highlighted with yellow-sample # 72 with very low ACE
activity –less than 30% of mean value. Bar highlighted with red-putative ACE mutation. C. Ratio of the rate of hydrolysis of the two substrates (ZPHL/
HHL ratio) in the tested samples. Data expressed as % of individual ZPHL/HHL ratio from mean value for whole population (1.05+0.05). Calculation of
this parameter was used primarily for identification of patients with ACE inhibitors in their blood (20): highlighted by red (high concentration) and
orange (low, but detectable concentration of ACE inhibitors). Bar highlighted by yellow (and arrowed)-from patient # 27. The results are shown as
mean values of duplicates. (Values of standard deviations, which were not exceeded 10%, were not shown for clarity).
doi:10.1371/journal.pone.0088001.g001
Catalytically - Defective ACE Mutation
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Immunological characterization of the mutant ACE
Ninety six-well plates (Corning, Corning, NY) were coated with
anti-ACE mAbs [23] and incubated with serum/plasma samples
or medium/lysates of CHO-ACE expressing cells After washing of
unbound ACE, plate-bound ACE activity was measured by adding
a substrate for ACE directly into wells [24].
Sequencing and genotyping
Genomic DNA was obtained from whole blood of patient # 27
and 13 exons of ACE gene (6th–12th, 19th–24th) were sequenced,
using primers designed by [25], obtained from SeqWright, Inc.
(Houston, TX) and designed in-house.
Molecular modeling of ACE
Analysis of the N domain was based on the recently published
[6] crystal structure (PDB accession number 3NXQ) and the C
domain was based on the structure resolved by Natesh et al. [7]
(PDB accession number 1O86). PYMOL (http://www.pymol.org)
was used to make the S333W substitution in silico using PyMol
Mutagenesis Wizard.
Site-directed mutagenesis and in vitro analysis of the
mutant ACEs
cDNAs encoding mutant ACE proteins were created by
GenScript USA Inc. (Piscataway, NJ) by mutation of the 1)
TCG codon for Ser at position 333 (somatic mature ACE
numbering [26] to codon TGG for Trp and 2) GAT codon for
Asp at position 562 to codon GGT, in expression vector based on
pcDNA3.1+/Hygro (Invitrogen Corp., Carlsbad, CA and con-
taining the full-length somatic ACE cDNA controlled by CMV
early promoter [27].
Figure 2. Effect of of anti-catalytic mAbs to N-domain active center for A and C for B) and from patient # 27 (arrowed in Fig. 1 C)
were incubated with mAbs which are anti-catalytic for the N-domain active center - i2H5 and 3A5 (10 mg/ml) [23,34]. Residual ACE
activity was determined with two ACE substrates as in Fig. 1. We also measured ZPHL/HHL ratio-as in [20] and in Fig. 1 C. Bars highlighted with yellow
- samples with values of ACE activity lower than mean 6 2SD for control sample without mAbs. Bars highlighted with red- samples with values of
ZPHL/HHL ratio higher than mean 6 2SD for control samples without mAbs. Data presented are mean 6 SD of 2–3 independent experiments in
duplicates). * p,0.05 vs. control serum.
doi:10.1371/journal.pone.0088001.g002
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Plasmids carrying the coding sequence for wild-type ACE and
above mutants were expressed in CHO cells using Plus Reagent
(Invitrogen Corp., Carlsbad, CA) for transient transfection and
generation of stable cell lines. Serum-free culture medium from
these cells was used as a source of the secreted (soluble) ACE (wild
type and mutants) for biochemical and immunological character-
ization. Lysate of these cells obtained with detergent Triton X-100
(0.5% in PBS) was used as a source of membrane-bound form of
WT and mutant ACE.
Western blot analysis of mutant ACE expression
Lysates from CHO-WT-ACE cells (with ACE activity of 5 mU/
ml using Hip-His-Leu) were compared to lysates from CHO-
ACE–S333W cells normalized by equal protein loading by SDS-
PAGE in 4–15% acrylamide Tris-HCl pre-cast SDS PAGE gels
(Bio-Red Laboratories, Hercules, CA). After electrophoretic
transfer of proteins to microporous PVDF-Plus membrane
Western blotting was performed exactly as in [4].
Kinetic assessment of AcSDKP hydrolysis by recombinant
ACE
An adapted plate assay was designed based on previously
published approach for N-acetyl-angiotensin I [28] using fluor-
escamine (4-phenylspiro[furan-2(3H),19-phthalan]-3,39-dione), a
reagent that forms fluorescent adducts exclusively with primary
amines [29]. 30 ml of 1 mM AcSDKP (Sigma-Aldrich Co.)
substrate in buffer (50 mM HEPES, pH 7.5, 100 mM NaCl,
10 mM ZnSO4) was warmed to 37uC in a 96-well plate. The assay
was commenced by the addition of 10 ml (10 mg total protein) pre-
warmed lysate, incubated for 30 minutes and stopped by the
addition of 50 ml 1 M HCl. The solution was neutralized by the
addition of 50 ml 1 M NaOH and the pH increased to 8.3 by the
addition of 100 ml 500 mM K2HPO4/KH2PO4 buffer pH 8.3.
10 ml of fluorescamine (2 mg/ml in acetone, Sigma-Aldrich Co.)
was added and the resulting mixture incubated for 3 minutes at
room temperature. Fluorescence intensities were measured at
lex = 390 nm and lem = 475 nm using a Cary Eclipse spectroflu-
orimeter (Varian Inc.). Changes in fluorescence compared to
empty vector lysate were converted to reaction velocities by the use
of a standard curve. The standard was constructed by complete
hydrolysis of various concentrations of AcSDKP by purified N-
domain using the same approach as above.
Results and Discussion
Identification of novel ACE mutations
Screening of serum ACE activity was performed in 84 cases
with pulmonary and extrathoracic sarcoidosis and unrelated
patients serving as controls and resulted in the identification of a
single case (#38) with ACE activity 5-fold higher than controls
(Fig. 1A and 1B). Further investigation led to the discovery that
this patient carried a novel ACE mutation-R532W [12]. ACE
activity in serum of 84 patients was determined with two artificial
‘‘short’’ substrates HHL and ZPHL (Fig. 1A and 1B). Fig. 1C
shows the ratio of the rate of hydrolysis of two ACE substrates,
Figure 3. Effect of of anti-catalytic mAbsto C domain active center on blood ACE activity. Serum samples from pools of healthy
volunteers (Control) and from patient # 27 (arrowed in Fig. 1 C) were incubated with mAbs which are anti-catalytic for the C -domain active center –
1E10 and 4E3 [7]. Residual ACE activity was determined with two ACE substrates as in Fig. 1. We also measured ZPHL/HHL ratio-as in [20] and in Fig.1
C Data presented are mean 6 SD of 2–3 independent experiments in duplicates). * p,0.05 vs. control serum.
doi:10.1371/journal.pone.0088001.g003
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ZFHL and HHL (ZPHL/HHL ratio), which was used primarily to
detect presence of ACE inhibitors in the blood of patients at the
time of blood sampling [20]. Eleven patients (red and orange bars
in Fig. 1C) had elevated ZPHL/HHL ratios suggesting the
presence of an ACE inhibitor. However, one patient (#27)
demonstrated a markedly lower ZPHL/HHL ratio of 0.7. This
represents the lowest ZPHL/HHL ratio we have determined in
more than 600 plasma/serum samples (not shown).
The two domains of ACE hydrolyze a range of natural and
synthetic substrates, but with different efficiencies [30–33]. The
two synthetic substrates ZPHL and HHL are used for determi-
nation of ACE activity in laboratories worldwide. These two
substrates display some contrasting enzymatic properties: the C
domain of human ACE hydrolyzes HHL at a much faster rate (9–
fold) than the N domain [30], whereas ZPHL is hydrolyzed at a
similar rate by both domains [23]. As a result, the ratio of the rates
of hydrolysis of these two substrates (ZPHL/HHL ratio) is
characteristic of different forms of ACE: somatic (two-domain)
human ACE - about 1-1.5, N-domain – 5–7, and C-domain - 0.6–
0.8 [20]. The selective inactivation or inhibition of the C-domain
in somatic ACE increases this ratio to higher values more
characteristic for the N-domain, whereas selective inactivation/
inhibition of the N-domain in somatic ACE decreases the ratio
toward lower values predicted for C-domain [20].
Therefore, the lower value of ZPHL/HHL ratio for patient #
27 suggested that the N domain active center could be inactivated
by a mutation in the active site of the enzyme. To further
investigate this, we incubated serum from patient # 27 (and two
controls - healthy individuals with normal ZPHL/HHL ratio) with
mAbs 3A5 and i2H5 which are anti-catalytic towards the N-
domain active center [23,34]. The inhibition of ACE activity from
patient # 27 by the anti-catalytic mAbs 3A5 and i2H5 was weaker
with substrate ZPHL than HHL (Fig. 2). This was surprising,
considering the substrate HHL is preferentially hydrolyzed by the
C-domain and the binding of anti-catalytic mAbs to the epitopes
localized on the N domain essentially did not affect the hydrolysis
of HHL by healthy individuals (controls) (Fig. 3). Moreover, mAbs
1E10 and 4E3 were less effective in the inhibition of ACE activity
with HHL than with ZPHL.
The pattern of inhibition of blood ACE activity from patient
#27 was similar for the short tripeptide ACE inhibitor enalaprilat
(Fig 4A) and long nonapeptide ACE inhibitor teprotide (Fig. 4B)
using substrate ZPHL. However, inhibition by these inhibitors
using substrate HHL was less effective: IC50 for enalaprilat was
2 nM for control serum and 7 nM for serum from patient # 27
(p,0.05); for teprotide IC50 values were 9.5 nM and 13.0 nM,
respectively (p,0.05). Thus, the data presented in Fig. 2-4 may
indicate that the putative ACE mutation in patient # 27 could
affect the overall catalytic ability, which can change the relative
ability to hydrolyse tested substrates rather than just inactivation of
the N-domain active center.
In order to characterize the conformation of blood ACE from
patient #27 we performed conformational fingerprinting of blood
ACE, using a panel of mAbs directed against 16 different epitopes
located on the N-and C-domain of catalytically active human
ACE [24]. We recently demonstrated that the pattern of
precipitation of ACE activity – (conformational fingerprint of
ACE) using a set of mAbs directed against 16 different epitopes of
human ACE provides a sensitive means of identifying changes in
local conformation of ACE due to inactivation, inhibition,
mutations, etc. [24]. Moreover, we successfully used this set of
mAbs to detect several new human ACE mutations and
characterized the conformation of Pro1199Leu [35], Trp1197Stop
[13], Q1069R [15], Y465D [4] ACE mutations.
Figure 4. Effect of ACE inhibitors on blood ACE activity. Serum samples (1/5 dilution in PBS) from pool of 10 healthy volunteers (control) and
from patient # 27 (arrowed in Fig. 1 C) were incubated with different concentration of ACE inhibitors: short –enalaprilat (A) and long –teprotide (B).
Residual ACE activity was determined with two ACE substrates (and ZPHL/HHL ratio) as in Fig. 2. Data presented are mean 6 SD of 2–3 independent
experiments in duplicates). * p,0.05 vs. control serum.
doi:10.1371/journal.pone.0088001.g004
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The immunoprecipitation profile of plasma ACE from subject
# 27 is quite different to that of plasma ACE from healthy
volunteers with normal ZPHL/HHL ratio (Fig. 5A). The binding
of 11 of the 16 mAbs ACE from this patient decreased, while
binding of mAb 1G12 and mAb 1E10 increased significantly. This
suggests that there is a change in overall conformation of ACE
from patient #27. We also estimated local conformational changes
of blood ACE from this patient, by calculating the relative binding
of mAbs to different epitopes on the N- and C-terminal domain.
Binding of several mAbs, sensitive to local conformational changes
in ACE (due to denaturation, glycosylation, and inhibitor binding)
[24,36] relative to binding of mAb 9B9, directed to the epitopes
resistant to such changes [37] is shown in Fig. 5B. These results
confirmed that the region on the surface of the N domain of ACE
containing overlapping epitopes for mAbs 1G12 and 6A12 and the
region on the C domain of ACE containing epitope for mAb
1E10, undergoes a significant conformational change.
We demonstrated previously that binding of mAbs 1G12 and
6A12 to blood ACE dramatically (3–4-fold) increased in the
presence of ACE inhibitors [36] ACE inhibitor enalaprilat
increased binding of mAb 6A12 to ACE from control and patient
# 27 to a similar extent, whereas increase in mAb 1G12 binding
to ACE from patient # 27 was lower to normal ACE from control
blood. Moreover, this difference was apparent only with substrate
Hip-His-Leu and not with Z-Phe-His-Leu (Fig. 5C). This suggests
that conformational changes in blood ACE of patient # 27 could
be very localized proximal to the region where Hip-His-Leu binds
to the N-domain active site.
Therefore fine analysis of enzymatic activity, sensitivity to ACE
inhibition and conformational analysis of blood ACE from patient
# 27 (Figures 1–5) unequivocally demonstrated profound local
and overall conformational changes in ACE from this patient,
which likely altered the interactions of ACE from this patient with,
at least, artificial ACE substrates.
We sequenced those exons of the ACE gene from this patient
which code amino acid residues comprising the N- and C-domain
active sites [26], or contribute to N-and C-domain substrate
specificity [38] - 6th–12th exon of the N domain and 19th–23th
exon of the C domain. We identified several known polymorphic
variants of ACE gene in patient # 27: i) rs 12709426
(c.1809A.G; p.D592G), which correspond to D563G substitution
- mature somatic ACE numbering [26] in 12th exon of ACE; ii)
rs12720737 in intron 23; and iii) rs4362 (c.3421T.C, synonymous
substitution in 1129 codon for Phe).
A heterozygous mutation was found in the 7th exon c.1119
C.G, p.S362W (Fig. 6A). Additional screening revealed that none
of the 100 randomly chosen genomic DNA samples from healthy
controls showed this mutation indicating that this substitution is
not a polymorphism. This mutation results in the substitution of a
highly conserved serine (Fig. 6B) with a tryptophan, which
corresponds to a S333W substitution in the N-domain of somatic
ACE. Unfortunately, other members of patient’s family (Fig. 6C),
were not available for analysis.
The mutation in the same codon of ACE coding for Ser333 of
mature ACE was found previously in at least six individuals in
North America (GenBank – rs142328237, http://www.ncbi.nlm.
Figure 5. Conformational fingerprinting of serum ACEs with a set of mAbs to ACE. A. Sixteen monoclonal antibodies were used to
precipitate ACE from sera. Immunoprecipitated ACE activity is presented as a normalized value (‘‘binding ratio’’), to highlight differences in
immunoprecipitation pattern (‘‘conformational fingerprint’’) among blood ACE from patient # 27 and blood ACE from healthy individuals (which
were expressed as 100%). B. Binding of several mAbs to serum ACE from control samples and serum from patient # 27-relative to binding by mAb
9B9. Data expressed as % of mAbs/9B9 binding ratio for serum from patient # 27 to that for control serum. Bars highlighted with yellow - samples
from serum of patient # 27 with values of precipitated ACE activity 20% lower than this value for control sample. Bars highlighted with red- samples
from serum of patient # 27 with values of precipitated ACE activity 20% higher than this value for control sample. C. Effect of ACE inhibitor
enalaprilat (100 nM) on binding of mAbs 1G12 and 6A12 to serum ACE from control samples and serum from patient # 27. All data presented as a
mean of 3–5 independent determinations. * p,0.05 indicates values shown is significantly different.
doi:10.1371/journal.pone.0088001.g005
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nih.gov/projects/SNP/). Besides, the S333W substitution, an
S333L substitution was found the GenBank in the same codon
which should have a lesser effect on the N domain active center
than the S333W substitution, due to the smaller size of the Leu
side chain, compared to Trp.
Functioning of ACE as an enzyme is not tolerated by this
(S362W) amino acid change (S333W for mature ACE protein)
according to Polyphen-2 analysis (http://genetics.bwh.harvard.
edu/pph2/, based on [39] which predicts that this mutation is
damaging with a probability 100%. SIFT software [http://sift.jcvi.
org/based on [40] also predicts damaging effect of this mutation:
SIFT Score: 0, Median Information Content: 2.4.
Analysis of the 3D-structure of the N domain, co-crystallized
with lisinopril, demonstrated that Ser333 is located deep in the
active site cleft close to lisinopril (Fig. 7A). Closer inspection of the
structure of the N-domain active center showed that the S333W
substitution could be responsible for the dramatic decrease in the
ZPHL/HHL ratio of the mutant ACE. The distance between
S333 and the P1 phenylalanine of the ACE inhibitor lisinopril of
about 6.2 Å is too far for a direct interaction with substrate, or
interference with the residues in the active center responsible for
substrate specificity or domain specificity of ACE inhibitors
(Fig. 7B). However, if the Trp is substituted for Ser333, rotation
about the side chain torsions x1 and x2 can result in a steric clash
with the P1 Phe of lisinopril. Similarly, with a more extended
ligand such as the N-domain selective phosphinic peptide inhibitor
RXP407, it is likely that the influence of steric hindrance of the P1
group with Trp333 would adversely affect its binding to the active
Figure 6. Identification of novel ACE mutation- Ser333Trp. A. Sequencing of ACE gene in patient # 27. Heterozygous mutation Ser333Trp
(S333W) in 7th exon was revealed by the sequencing 6–12th, 19th–24th exons of ACE gene of this patient. B. Alignment of amino acid sequences from
ACE of several vertebrate species indicates that S333 and the flanking residues are highly conserved. The numbering relates to the mature ACE. C.
Family tree of patient # 27 with new (S333W) mutation in ACE gene. Genotyped individual with S333W mutation are indicated by yellow color.
Individuals found to have low value of ZPHL/HHL ratio for serum ACE are marked by upward pointing arrows. Following abbreviations are used for
known clinical diagnoses: SCD-Sickle Cell Disease, DM–diabetes mellitus, HTN–hypertension. Among individuals in whom both genotyping and
serum ACE determination was performed, there was 100% concordance between presence or absence of the S333W mutation and low or non-
elevated ZPHL/HHL ratio for serum ACE, respectively.
doi:10.1371/journal.pone.0088001.g006
Figure 7. Localization of ACE mutation (S333W) in the N
domain of human ACE. A. A molecular surface representation of the
N-domain crystal structure (PDB code 2C6N [6] showing the active-site
channel and the bound lisinopril (yellow stick representation). The
surface of Ser333 is shown in purple. Helices a1, a2 and a3 that form a
cover over the central channel have been deleted to visualize the
inhibitor and the location of Ser 333. B. Details of the active site of a
ribbon diagram of the N-domain where Ser333 has been replaced with
a Trp (red stick representation) using PyMOL Mutagenesis Wizard
(DeLano Scientific, Palo Alto, CA, U.S.A). Ser333 is located 6.2 Å from the
P1 Phe of the ACE inhibitor lisinopril shown in yellow. Whereas Trp333
could potentially result in a steric clash with the P1 residue of the
bound ligand.
doi:10.1371/journal.pone.0088001.g007
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site (Fig. 8). Thus, these molecular models suggest that substitution
of Ser333 by Trp could be responsible for the changes in the
substrate specificity that we observed with blood ACE of the
patient # 27.
Characterization of S333W ACE Mutant
To elucidate the mechanism by which S333W substitution (or
D563G) might be responsible for the changes in enzyme activity of
this blood (and perhaps tissue) ACE in the affected individuals, we
performed site-directed mutagenesis of human recombinant
somatic ACE. These mutants of somatic ACE were expressed in
CHO cells and the biochemical and immunological characteristics
of these mutants were compared with WT somatic ACE.
As expected, based on published crystal structures of the N
domains with ACE inhibitors [6,41], D563G substitution did not
cause any changes in kinetic properties of recombinant mutant
ACE. In contrast, the recombinant mutant (S333W) expressed in
CHO cells exhibited a dramatic decrease in ZPHL/HHL ratio
(Fig. 9A) when compared to wild-type enzyme. The 65% decrease
of ZPHL/HHL ratio for recombinant S333W ACE was signifi-
cantly higher than the 33% we observed for blood ACE from
patient #27 (Fig. 1C). This could be explained by the fact that
blood of patient #27 contains a mixture of WT and mutant alleles
of ACE, and thus the apparent ZPHL/HHL ratio of ACE
determined in plasma of this patient is not an accurate reflection of
this parameter. Mutant recombinant membrane-bound ACE also
demonstrated lower sensitivity towards ACE inhibitor enalaprilat
with substrate Hip-His-Leu than towards Z-Phe-His-Leu (Fig. 9B),
similar to what we observed with plasma ACE from patient # 27
(Fig. 4). Therefore, these data unequivocally demonstrate that the
heterozygous S333W substitution found in ACE of patient # 27 is
largely responsible for the altered enzymatic activity of blood
ACE, and, likely, tissue ACE in this patient.
We also performed conformational fingerprinting of recombi-
nant S333W ACE (Fig. 9C–E) in the same way as we did for
plasma ACE from patient #27 (Fig. 5). The conformational
fingerprint of mutant ACE (i.e. the pattern of binding of 16 mAbs
to ACE) was quite different to that seen for WT ACE, supporting
the hypothesis that a single amino acid substitution can cause
overall conformational changes in the ACE molecule as well as
local conformational changes close to this residue. However these
changes were greatly dependent on the type of ACE and on ACE
substrates used.
The overall precipitation of ACE activity (measured with Hip-
His-Leu as a substrate) from membrane-bound mutant ACE by
mAbs directed to the epitopes localized on the N-domain was
lower than that by mAbs to C-domain. The mean S333W/WT
ratio of ACE activity precipitation for 8 mAbs to the N domain
calculated from the data presented in Fig.9C was 0.7960.13
versus 1.0660.11 (p,0.05) for mAbs directed to C domain, and,
especially, binding of mAbs i2H5, 1G12 and 6A12 whose epitopes
overlap [23,36] decreased significantly. The pattern of overall
precipitation of ACE activity from membrane-bound mutant
ACE, measured with ZPHL was quite different from that
measured with HHL, but also differs between N and C domain
mAbs. Furthermore, the changes due to the S333W mutation were
more prominent for mAbs having overlapping epitopes– i2H5,
1G12,and 6A12 (Fig. 9D).
These data suggest that the S333W substitution leads to local
conformational changes in the N-domain of the mutant ACE
(selective, local denaturation of the N domain of ACE) which then
leads to changes in the hydrolysis of some substrates.
Figure 8. Critical residues in the active center of the N-domain of mutant ACE. The RXP407–N-domain co-crystal structure of the N domain
of ACE with N-domain specific inhibitor RXP407 - PDB accession code 3NXQ [42]. Key amino acids in the N domain crucial for substrate specificity and
ACE inhibition are denoted by somatic ACE numbering and are shown as green sticks. The catalytic zinc ion is shown in slate blue and RXP407 in blue.
A water molecule that could possibly be involved in an interaction between the C-terminal amide of RXP407 and Thr358 is given as a small blue
sphere. Image generated using PyMOL software and Ser333 has been replaced with a Trp (purple stick representation) using PyMOL Mutagenesis
Wizard (v 0.99, DeLano Scientific).
doi:10.1371/journal.pone.0088001.g008
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We also assessed the ZPHL/HHL hydrolysis by mutant ACE
bound to antibodies. The ZPHL/HHL ratio of WT ACE bound
to mAbs did not change significantly except for mAb 4E3 which is
strongly anti-catalytic for the C domain active center [7].
However, the putative selective denaturation of the N domain of
mutant ACE was partially restored after binding to those mAbs
which showed impaired binding (Fig. 9C). The ZPHL/HHL ratios
for the mutant ACE precipitated by mAbs to the C-domain was
the same as that for mutant ACE in solution, whereas the ZPHL/
HHL ratio for mutant ACE bound to mAbs 3A5, i2H5, 1G12 and
Figure 9. Characterization of recombinant mutant (S333W) ACE. A. ACE activity of the membrane-bound form of ACE of CHO cells (lysates)
transiently expressing WT and mutant ACE was determined as in Fig. 1. Ratio of hydrolysis of the two substrates (ZPHL/HHL ratio) in the tested
samples are presented as mean (6SD) from 4 independent experiments. *p,0.05 vs. WT. B. Effect of ACE inhibitors and anti-catalytic mAbs on
mutant ACE activity. Lysates form CHO cells expressing mutant and WT membrane-bound ACE were incubated with ACE inhibitor enalaprilat
(100 nM). Residual ACE activity was determined with both substrates and ZPHL/HHL ratio was determined as in A. C–F. Conformational fingerprinting
of mutant ACE. C–D. Membrane-bound WT and mutant ACE (lysates from corresponding CHO cells) were normalized to achieve 5 mU/ml ACE
activity with Hip-His-Leu as substrate and incubated in microtiter plate wells covered with 16 mAbs to human ACE as in Fig. 4 Data (mean 6 SD of 2–
3 independent experiments in duplicate) are expressed as ratio of ACE activity with HHL (C) and ZPHL (D) precipitated by mAbs from mutant ACE to
that of WT ACE. Bars highlighted with yellow – the values of precipitated ACE activity from mutant ACE was 20% lower than this value for WT. Bars
highlighted with red- the values of precipitated ACE activity from mutant ACE was 20% higher than this value for WT. E–F. The data presented in C
and D were expressed as the ZPHL/HHL ratio of ACE activity precipitated by each mAb. Data are mean 6 SD of 6–8 independent experiments in
duplicate. Bars highlighted with yellow – the values of ZPHL/HHL ratio of the precipitated ACE activity was 20% lower than this value for this type of
ACE in solution. Bars highlighted with red - the values of ZPHL/HHL ratio of precipitated ACE activity was 20% higher than this value for this type of
ACE in solution. * - p,0.05 vs. ZPHL/HHL ratio for corresponding values of WT and mutant ACE in solution (horizontal lines in E and F). The ratio for
any duplicate samples of WT ACE or mutant ACE for each mAb was approximately 1.0 and the SD was less than 10%.
doi:10.1371/journal.pone.0088001.g009
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6A12 t significantly increased, demonstrating a shift towards
higher values characteristic of native two-domain ACE (Fig.9E).
We already observed a local chaperone-like effect of mAbs to the
C-domain of ACE directed to the regions close to a mutation in
the C-domain - Q1069R [15].
We also performed Western blotting of cell lysates from CHO-
WT-ACE and CHO-S333W-ACE using mAb to denatured
human ACE -1D8 which recognize sequential epitope in the C
domain [42]. Western blot of recombinant wild-type and
membrane-bound mutant ACE with mAb 1D8 demonstrates the
amount of mutant ACE protein loaded for electrophoresis was
three times lower than the amount of wild-type ACE (Fig. 10),
despite the fact that ACE activity of both proteins was equilibrated
with Hip-His-Leu. Bearing in mind that the ACE activity in
mutant protein determined with substrate Z-Phe-His-Leu was 3-
fold less, it is likely that mutant ACE hydrolysed substrate Hip-
His-Leu roughly 3-fold faster than wild type N domain.
Our data indicates that dramatic changes in enzymatic activity
of mutant S333W ACE (ZPHL/HHL ratio) could be due to two
reasons: 1) the presence of a bulky Trp in the active site cleft that
might affect the binding of ACE substrates due to steric hindrance;
and 2) selective denaturation of the N-domain of mutant ACE,
perhaps due to incorrect folding and trafficking to the cell surface.
We demonstrated that this mutation (S333W) abolished
substrate specificity of the N-domain at least for two artificial
substrates Hip-His-Leu and Z-Phe-His-Leu. The N-terminal
domain of WT human ACE cleaves Hip-His-Leu much slower
than the C-domain [23,30], whereas the N-domain active center
cleaves substrates such as LH-RH and AcSDKP much more
efficiently [31,43]. Several active site residues determine the
substrate specificity of the N- and C-domains active centers of
somatic ACE [15,38].
Therefore we tested the effect of the S333W mutation on the
hydrolysis of the natural substrate AcSDKP (Fig. 11). Stable
transfection of CHO cells with WT- and S333W-ACE revealed a
similar decrease in enzymatic activity for the mutant ACE to that
seen with transient transfections using substrates HHL and ZPHL.
Hydrolysis of the N-domain selective substrate AcSDKP by
S333W was approximately 5-fold lower than that of WT ACE
(Fig. 11D). These data suggests that patients with the S333W
mutation might have increased endogenous levels of AcSDKP.
(Unfortunately, repeat blood/urine samples from this patient as
well as blood samples from the other 6 individuals from the NCBI
data base were not available for further analysis). Nevertheless we
believe that the carriers of this mutation might demonstrate
decreased predisposition to certain types of fibrosis due to
increased levels of the anti-fibrotic AcSDKP.
The rising burden of pulmonary fibrosis in the U.S. currently
accounts for more than 40 000 deaths annually. Moreover, few
effective drugs are presently available for the treatment of
pulmonary fibrosis. Activation of the renin-angiotensin system
(RAS) and production of Angiotensin II is associated with tissue
fibrosis, therefore ACE inhibition and/or AII antagonism has
been suggested as a possible anti-fibrotic therapy -see for review
[18].
AcSDKP is a natural inhibitor of hematopoietic stem cell
proliferation [17] and natural substrate for N-domain active center
of ACE [43] has recently emerged as an anti-fibrosis molecule-for
review see [18,44]. Several in vivo studies demonstrated that
AcSDKP injection [45–47] or specific prevention of AcSDKP
degradation [19] may suppress fibrosis in several animal models.
ACE is the primary enzyme responsible for the degradation of
AcSDKP and its actions in producing the profibrotic molecule
angiotensin II and in degrading the anti-fibrotic molecule
AcSDKP suggest that ACE and the RAS might be important in
some fibrotic diseases [19]. Anti-fibrotic effect of AcSDKP are
likely mediated via prevention of TGFb-induced Smad2 phos-
phorylation-for review see [18].
The inhibition of ACE in both mice and humans causes a 5-fold
increase in AcSDKP levels [48]. A similar increase in AcSDKP is
observed in ACE-null mice and mice with enzymatically inactive
N-domain [49]. The carriers of S333W mutation in the active
center of the N domain of ACE (where almost exclusive hydrolysis
of AcSDKP occurs) could be protected to some extent from
AcSDKP-dependent lung (and other tissues) fibrosis.
In summary, we identified a patient with a novel mutation of
ACE-S333W. In silico analysis demonstrated that this mutation was
localized in the S1 pocket of the active site of the N domain and it
is likely the bulky Trp (W) would affect the binding of ACE
substrates due to steric hindrance. We studied the effect of this
mutation on the hydrolysis of several artificial and natural
substrates were determined. Mutant ACE (S333W) expressed in
CHO cells decreased significantly the hydrolysis of N-domain
Figure 10. Mutant ACE protein quantification (Western Blot-
ting). CHO cells were transiently transfected with plasmids coding for
wild-type (WT) and mutant (S333W) ACE (4 mg of plasmid DNA per
35 mm dish). The lysates of these cells (normalized by equal protein
loading of 10 mg per lane) were subjected to SDS-PAGE (4–15%
gradient gel) in reducing conditions for Western blotting (A) or protein
quantification (B). A. Western blotting was performed with mouse mAb
1D8 that recognizes the denatured epitope on the C-domain of human
ACE [45]. Proteins transferred on PVDF-Plus membrane were revealed
with 1/5 dilution of culture medium from hybridoma cells producing
mAb 1D8. Molecular weight markers are shown by arrows on the left of
panel A, which is a representative experiment. B. The relative amount of
WT and mutant ACE revealed by Western blotting with mAb 1D8 (A)
was quantified by the image analysis (densitometry) using ImageJ
software (NIH). Data are expressed as mean 6 SD of 2 independent
measurements.
doi:10.1371/journal.pone.0088001.g010
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specific substrates, including the anti-fibrotic Ac-SDKP. Besides,
expression of mutant ACE in CHO cells allowed us to study
immunoreactivity, conformation, rate of ACE shedding and
trafficking to the cell surface for the mutant ACE. Using a novel
conformational fingerprinting approach for ACE, we demonstrat-
ed that S333W mutation lead to conformational changes in whole
ACE, and specifically (preferentially) in the N-domain. Therefore,
this study provides important insights into the mechanism by
which the novel ACE mutation (S333R) results in changed kinetic
characteristics of mutant ACE.
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